New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program

U.S. regulatory approvals would trigger eligibility for separate $30 million second-line and $100 million first-line milestone payments.

Rhea-AI Summary

Cullinan Therapeutics (CGEM) initiated an FDA application submission for zipalertinib plus chemotherapy as a first-line treatment for a mutation-defined lung cancer. The application covers previously untreated, locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. Under Real-Time Oncology Review, clinical data can be reviewed before the complete application; Cullinan expects submission completion by year-end 2026.

The Phase 3 REZILIENT3 trial met its primary endpoint, showing a statistically significant improvement in median progression-free survival—time without disease worsening—versus chemotherapy alone. A separate application for zipalertinib monotherapy after platinum-based chemotherapy remains under FDA review, with a February 27, 2027 target action date. Cullinan is eligible for $30 million upon second-line U.S. approval and $100 million upon first-line U.S. approval.

6 points · 2 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointPhase 3 REZILIENT3 met its primary endpoint, significantly improving median progression-free survival versus chemotherapy alone.
• Major point. Forward-looking: it has not happened yet and may not happen.Cullinan is eligible for $100 million upon first-line U.S. regulatory approval. 10% of market cap
• Moderate pointFirst-line combination application submission initiated under FDA Real-Time Oncology Review.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Cullinan is eligible for $30 million upon second-line U.S. regulatory approval. 3% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Cullinan expects NDA submission completion by year-end 2026.
• Minor pointFDA Breakthrough Therapy designation covers zipalertinib for locally advanced or metastatic disease after platinum-based chemotherapy.

Negative

• Moderate pointSecond-line monotherapy accelerated-approval application remains under FDA review, with a February 27, 2027 target action date.
• Minor pointFirst-line application submission remains incomplete; FDA approval is still pending.

Key Figures

NDA submission completion: year-end 2026 Second-line U.S. approval milestone: $30 million First-line U.S. approval milestone: $100 million +1 more

NDA submission completion

year-end 2026

Expected completion of the zipalertinib combination NDA submission

Second-line U.S. approval milestone

$30 million

Milestone payment Cullinan is eligible to receive upon regulatory approval

First-line U.S. approval milestone

$100 million

Milestone payment Cullinan is eligible to receive upon regulatory approval

PDUFA target action date

February 27, 2027

Separate monotherapy NDA remains under FDA review

Previous Clinical trial Reports

2 past events · Latest: Sep 13

Same Type 2 events

1. Sep 13

   Phase 3 results

   24h Move

   -0.9%

   Reported 14.5 versus 8.5 months median progression-free survival for combination versus chemotherapy.

2. Aug 12

   Phase 3 endpoint

   24h Move

   +0.2%

   Trial met primary progression-free survival endpoint; companies planned to pursue U.S. approval.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

new drug application, real-time oncology review, progression-free survival, pdufa

4 terms

new drug application regulatory

"initiation of a New Drug Application (NDA) submission"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

real-time oncology review regulatory

"under the FDA’s Real-Time Oncology Review (RTOR) program"

A regulatory process in which reviewers assess clinical data and application materials for a cancer therapy as they are submitted, instead of waiting for a complete package. By allowing questions to be answered and issues resolved during the submission rather than afterward, it can speed up decisions and reduce surprise delays. For investors, that means greater predictability around potential approvals or setbacks and a faster path to a drug reaching the market, similar to editing a book chapter-by-chapter rather than after the whole manuscript is finished.

progression-free survival medical

"improvement in median progression-free survival"

Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.

pdufa regulatory

"Prescription Drug User Fee Act (PDUFA) target action date"

PDUFA is the Prescription Drug User Fee Act, the U.S. law under which drug companies pay fees that fund the FDA's review of new medicines. In company news the term usually appears as the PDUFA date, the target deadline by which the FDA aims to decide on a drug application; that date tells investors when to expect the approval or rejection decision for the product.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

In the Phase 3 REZILIENT3 study, zipalertinib combination therapy demonstrated longest median progression-free survival observed to date in first-line EGFR exon20ins NSCLC 

After agreement with the U.S. FDA, Real-Time Oncology Review program submission process initiated; completion of NDA submission expected by year-end 2026

CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced the initiation of a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertion (ex20ins) mutations under the FDA’s Real-Time Oncology Review (RTOR) program.

The RTOR program allows sponsors to submit clinical data in advance of the complete application to facilitate earlier review of efficacy and safety results. Completion of the NDA submission is expected by year-end 2026.

The NDA submission is based on data from the Phase 3 REZILIENT3 trial, which met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in median progression-free survival for zipalertinib plus chemotherapy compared to chemotherapy alone. These results were recently presented at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC) during a Presidential Symposium, where potentially practice-changing clinical data are highlighted.

Zipalertinib holds FDA Breakthrough Therapy designation for the treatment of patients with locally advanced or metastatic EGFR ex20ins NSCLC who have previously received platinum-based chemotherapy. An NDA seeking accelerated approval for zipalertinib monotherapy in this indication remains under FDA review, with a Prescription Drug User Fee Act (PDUFA) target action date of February 27, 2027.

Cullinan Therapeutics is eligible to receive $30 million and $100 million in milestone payments upon second-line and first-line U.S. regulatory approvals, respectively.

About Zipalertinib

Zipalertinib (development code: CLN-081/TAS6417) is an orally available small molecule designed to target activating mutations in EGFR. The molecule was selected because of its ability to inhibit EGFR variants with exon 20 insertion mutations. Zipalertinib is designed as a next generation, irreversible EGFR inhibitor for the treatment of a genetically defined subset of patients with non-small cell lung cancer. Zipalertinib is investigational and has not been approved by any health authority.

Zipalertinib is being developed by Taiho Oncology, Inc., its parent company, Taiho Pharmaceutical Co., Ltd., and in collaboration with Cullinan Therapeutics, Inc. in the U.S.

About EGFR Exon 20 Insertion Mutations

NSCLC is a common form of lung cancer and up to 4% of all cases globally have EGFR ex20ins.¹ In the United States, approximately 16% of patients with NSCLC harbor EGFR mutations,¹ with insertions at exon 20 accounting for up to 12% of these mutations.²

About Cullinan Therapeutics

Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, disease-modifying T cell engagers for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.

 Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding the company’s beliefs and expectations regarding the clinical development of zipalertinib, the safety and efficacy profile of zipalertinib and its potential to address unmet medical need, the potential of zipalertinib to become a first-line treatment option, the anticipated timing of the completion of the NDA submission under the RTOR program and other statements that are not historical facts. The words “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “potential,” “project,” “pursue,” “will,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These risks include, but are not limited to, the following: uncertainty regarding the timing and results of clinical trial data and regulatory submissions; the risk that any NDAs, INDs or other global regulatory submissions we may file with the United States Food and Drug Administration or other global regulatory agencies are not accepted or cleared on our expected timelines, or at all; the success of our clinical trials and preclinical studies; the risks related to our ability to protect and maintain our intellectual property position; the risks related to manufacturing, supply, and distribution of our product candidates; the risk that any one or more of our product candidates, including those that are co-developed, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical trials will not be predictive of future results in connection with future studies or clinical trials; the effect of changes in global economic conditions, including uncertainties related to international trade policies, tariffs and supply chain dynamics on our business and operations; and the success of any collaboration, partnership, license or similar agreements. These and other important risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including under the caption “Risk Factors” in our most recent Annual Report on Form 10-K and subsequent filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except to the extent required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Moreover, except as required by law, neither the company nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made.

Investors  
Nick Smith  
+1 401.241.3516  
nsmith@cullinantx.com

Media 

Rose Weldon  
+1 215.801.7644   
rweldon@cullinantx.com

References

1. Burnett H, Emich H, Carroll C, et al. Epidemiological and clinical burden of EGFR exon 20 insertion in advanced non-small cell lung cancer: a systematic literature review. PLOS ONE. 2021;16(3): e0247620. Available at: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0247620.
2. Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. Journal of Thoracic Oncology. 2018 Jul 5;13(10):1560–1568. Available at: https://www.jto.org/article/S1556-0864(18)30770-6/pdf.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does Cullinan expect to complete the first-line zipalertinib FDA application?

Cullinan expects to complete the New Drug Application submission by year-end 2026. The application seeks approval for zipalertinib plus platinum-based chemotherapy in previously untreated, locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations.

What did Cullinan's Phase 3 REZILIENT3 zipalertinib trial show?

REZILIENT3 met its primary endpoint, demonstrating a statistically significant improvement in median progression-free survival for zipalertinib plus chemotherapy compared with chemotherapy alone. Progression-free survival measures time without disease worsening.

Who is developing zipalertinib with Cullinan Therapeutics?

Zipalertinib is being developed by Taiho Oncology and its parent, Taiho Pharmaceutical, in collaboration with Cullinan Therapeutics in the United States.